Nascent Biotech Retires Liabilities with Non-Dilutive Funding
Nascent Biotech and Hisun Announce an Exclusive License Agreement for the Development and Commercialization of Nascent’s Primary Asset, Pritumumab, in Mainland China
Nascent Biotech Announces Orphan Drug Designation for Pancreatic Cancer
Nascent Biotech, Inc. Announces the Addition of Mr. Doug Karas to its Board of Directors
Nascent Biotech, Inc. Announces the Addition of Dr. Ralph Zipper to Advisory Board
Nascent Biotech, Inc. Announces an Agreement Reducing Its Liabilities By $1.4 Million
Get the Nascent Newsletter
Stay in touch with news from Nascent Biotech when you sign up for our free newsletter.
Contact Nascent
Communicate with Nascent Biotech the quick and easy way – through our contact form.